Transwell assays revealed that PRMT6 silencing significantly attenuated the invasion of LN229 and U87 cells, while EZH2 overexpression restored the invasive ability of PRMT6-silenced glioblastoma cells (Fig. 4B, C). The gene discussed is PRMT6; the disease is glioblastoma.